Clinical Trial

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Protocol Amendment History 3 changes
notable Trial sites expanded: 5 -> 41 locations 2026-08-14
critical Recruitment opened 2026-04-23
notable Trial sites expanded: 0 -> 5 locations 2026-04-23
Trial Details
NCT Number NCT07459647
Lead Sponsor MapLight Therapeutics
Conditions Schizophrenia
Enrollment 500 participants
Start Date 2026-03-31
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-13